AAAAAA
Results:
1-25
|
Results: 25
Authors:
Fondrinier, E
Boisdron-Celle, M
Chassevent, A
Lorimier, G
Gamelin, E
Citation: E. Fondrinier et al., Experimental assessment of tumor growth and dissemination of a microscopicperitoneal carcinomatosis after CO2 peritoneal insufflation or laparotomy - Clinical and biological results of a randomized animal study, SURG ENDOSC, 15(8), 2001, pp. 843-848
Authors:
Misset, JL
Vennin, P
Chollet, P
Pouillart, P
Laplaige, P
Frobert, JL
Castera, D
Fabro, M
Langlois, D
Cortesi, E
Lucas, V
Gamelin, E
Laadem, A
Otero, J
Citation: Jl. Misset et al., Multicenter phase II-III study of oxaliplatin plus cyclophosphamide vs. cisplatin plus cyclophosphamide in chemonaive advanced ovarian cancer patients, ANN ONCOL, 12(10), 2001, pp. 1411-1415
Authors:
Becouarn, Y
Gamelin, E
Coudert, B
Negrier, S
Pierga, JY
Raoul, JL
Provencal, J
Rixe, O
Krisch, C
Germa, C
Bekradda, M
Mignard, D
Mousseau, M
Citation: Y. Becouarn et al., Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patients, J CL ONCOL, 19(22), 2001, pp. 4195-4201
Authors:
Gaci, M
Morel, O
Sultan, AM
Giraud, P
Muratet, JP
Gamelin, E
Jallet, P
Citation: M. Gaci et al., False-positive suspicion of a thyroid metastatic lesion by In-111 pentetreotide uptake in a toxic nodular goiter, CLIN NUCL M, 26(6), 2001, pp. 579-581
Authors:
Diabira, S
Rousselet, MC
Gamelin, E
Soulier, P
Jadaud, E
Menei, P
Citation: S. Diabira et al., PCV chemotherapy for oligodendroglioma: response analyzed on T2 Weighted-MRI, J NEURO-ONC, 55(1), 2001, pp. 45-50
Authors:
Andre, T
Colin, P
Louvet, C
Gamelin, E
Bouche, O
Achille, E
Colbert, N
Boaziz, C
Piedbois, P
Tubiana-Mathieu, N
Boutan-Laroze, A
Flesch, M
Billiau, V
Buyse, M
de Gramont, A
Citation: T. Andre et al., Randomized adjuvant study comparing two schemes of 5-fluorouracil and leucovorin in stage B2 and C colon adenocarcinoma: Study design and preliminarysafety results, SEMIN ONCOL, 28(1), 2001, pp. 35-40
Authors:
Grolleau, F
Gamelin, L
Boisdron-Celle, M
Lapied, B
Pelhate, M
Gamelin, E
Citation: F. Grolleau et al., A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels, J NEUROPHYS, 85(5), 2001, pp. 2293-2297
Authors:
Boisdron-Celle, N
Lebouil, A
Allain, P
Gamelin, E
Citation: N. Boisdron-celle et al., Pharmacokinetic properties of platinium derivatives, B CANCER, 88, 2001, pp. S14-S19
Authors:
Lortholary, A
Abadie-Lacourtoisie, S
Guerin, O
Mege, M
De Rauglaudre, G
Gamelin, E
Citation: A. Lortholary et al., Carcinoma of unknown primary site: 311 cases, B CANCER, 88(6), 2001, pp. 619-627
Authors:
Bensmaine, MA
Marty, M
de Gramont, A
Brienza, S
Levi, F
Ducreux, M
Francois, E
Gamelin, E
Bleiberg, H
Cvitkovic, E
Citation: Ma. Bensmaine et al., Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) +/- folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients, BR J CANC, 85(4), 2001, pp. 509-517
Authors:
Graham, MA
Lockwood, GF
Greenslade, D
Brienza, S
Bayssas, M
Gamelin, E
Citation: Ma. Graham et al., Clinical pharmacokinetics of oxaliplatin: A critical review, CLIN CANC R, 6(4), 2000, pp. 1205-1218
Authors:
Bensmaine, MA
de Gramont, A
Brienza, S
Marty, M
Levi, F
Ducreux, M
Francois, E
Gamelin, E
Bleiberg, H
Bleuzen, P
Simon, J
Cvitkovic, E
Citation: Ma. Bensmaine et al., Factors predicting for efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU)+/- folinic acid (FA) in a compassionate-use cohort of 370 5-FU-resistant advanced colorectal cancer (CRC) patients, EUR J CANC, 36(18), 2000, pp. 2335-2343
Authors:
Lortholary, A
Maillard, P
Delva, R
Boisdron-Celle, M
Perard, D
Vernillet, L
Besenval, M
Gamelin, E
Citation: A. Lortholary et al., Docetaxel in combination with 5-fluorouracil in patients with metastatic breast cancer previously treated with anthracycline-based chemotherapy: a phase I, dose-finding study, EUR J CANC, 36(14), 2000, pp. 1773-1780
Authors:
Allain, P
Heudi, O
Cailleux, A
Le Bouil, A
Larra, F
Boisdron-Celle, M
Gamelin, E
Citation: P. Allain et al., Early biotransformations of oxaliplatin after its intravenous administration to cancer patients, DRUG META D, 28(11), 2000, pp. 1379-1384
Authors:
Terret, C
Erdociain, E
Guimbaud, R
Boisdron-Celle, M
McLeod, HL
Fety-Deporte, R
Lafont, T
Gamelin, E
Bugat, R
Canal, P
Chatelut, E
Citation: C. Terret et al., Dose and time dependencies of 5-fluorouracil pharmacokinetics, CLIN PHARM, 68(3), 2000, pp. 270-279
Authors:
Boisdron-Celle, M
Gamelin, E
Citation: M. Boisdron-celle et E. Gamelin, Platinum compounds-taxanes pharmacologic interactions, B CANCER, 87, 2000, pp. 30-33
Authors:
Boisdron-Celle, M
Boulanger, N
Gamelin, E
Citation: M. Boisdron-celle et al., Pharmacokinetic monitoring, B CANCER, 87(1), 2000, pp. 86-92
Authors:
Gamelin, E
Boisdron-Celle, M
Citation: E. Gamelin et M. Boisdron-celle, Dose monitoring of 5-fluorouracil in patients with colorectal or head and neck cancer - status of the art, CR R ONC H, 30(1), 1999, pp. 71-79
Authors:
Brienza, S
Bensmaine, MA
Soulie, P
Louvet, C
Gamelin, E
Francois, E
Ducreux, M
Marty, M
Andre, T
de Braud, F
Bleiberg, H
Segal, V
Itzhaki, M
Cvitkovic, E
Citation: S. Brienza et al., Oxaliplatin added to 5-fluorouracil-based therapy (5-FU +/- FA) in the treatment of 5-FU-pretreated patients with advanced colorectal carcinoma (ACRC): Results from the European compassionate-use program, ANN ONCOL, 10(11), 1999, pp. 1311-1316
Authors:
Felizot, L
Lortholary, A
Tuchais, C
Delva, R
Gamelin, E
Citation: L. Felizot et al., Unique bone metastasis in the foot disclosing carcinoma of the rectum, PRESSE MED, 28(34), 1999, pp. 1879-1879
Authors:
Gamelin, E
Boissdron-Celle, M
Guerin-Meyer, V
Delva, R
Lortholary, A
Genevieve, F
Larra, F
Ifrah, N
Robert, J
Citation: E. Gamelin et al., Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage, J CL ONCOL, 17(4), 1999, pp. 1105-1110
Authors:
Fondrinier, E
Gamelin, E
Verriele, V
Citation: E. Fondrinier et al., Inflammatory breast metastasis from primary ovarian cancer: case report, EUR J GYN O, 20(1), 1999, pp. 16-17
Authors:
Gamelin, E
Mertins, SD
Regis, JT
Mickley, L
Abati, A
Worrell, RA
Linehan, WM
Bates, SE
Citation: E. Gamelin et al., Intrinsic drug resistance in primary and metastatic renal cell carcinoma, J UROL, 162(1), 1999, pp. 217-224
Authors:
Menei, P
Venier, MC
Gamelin, E
Saint-Andre, JP
Hayek, G
Jadaud, E
Fournier, D
Mercier, P
Guy, G
Benoit, JP
Citation: P. Menei et al., Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of glioblastoma - A pilot study, CANCER, 86(2), 1999, pp. 325-330
Authors:
Bates, SE
Zhan, ZR
Regis, J
Gamelin, E
Citation: Se. Bates et al., Measuring MDR-1 by quantitative RT-PCR, METH MOL M, 28, 1999, pp. 63-81
Risultati:
1-25
|